The two formulations of exenatide, exenatide once weekly (ExQW) and exenatide twice daily (ExBID), both approved for the treatment of T2DM in the US and Europe, provide continuous or intermittent GLP-1 receptor activation, respectively. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.